In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Third Harmonic Bio, Inc. (THRD – Research Report). The company’s shares opened today at $9.06.
According to TipRanks, Thome is a 3-star analyst with an average return of 3.4% and a 47.42% success rate. Thome covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, United Therapeutics, and Axsome Therapeutics.
The analyst consensus on Third Harmonic Bio, Inc. is currently a Moderate Buy rating.
Based on Third Harmonic Bio, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.34 million. In comparison, last year the company had a GAAP net loss of $8.21 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Third Harmonic Bio, Inc. (THRD) Company Description:
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company’s lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
